Related Experiment Video
Updated: Mar 13, 2026
12:03
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
18.5K
Azilsartan: Novel Angiotensin Receptor Blocker
Ramesh R Dargad1, Jai D Parekh2, Rohit R Dargad3
1Consulting Physician and Cardiologist, Lilavati, Seven Hills and L.H. Hiranandani Hospital.
The Journal of the Association of Physicians of India
|October 13, 2016
Summary
Azilsartan medoxomil, a new angiotensin receptor blocker (ARB), demonstrates superior efficacy in lowering systolic blood pressure compared to other ARBs and ACE inhibitors. It offers a similar safety profile and potential benefits beyond blood pressure control.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Nephrology
Background:
- Hypertension remains a significant global health concern.
- Angiotensin receptor blockers (ARBs) are a key class of antihypertensive medications.
- Azilsartan medoxomil represents a newer agent within the ARB class.
Purpose of the Study:
- To evaluate the efficacy and safety of Azilsartan Medoxomil.
- To compare Azilsartan Medoxomil with existing ARBs and ACE inhibitors.
- To explore potential benefits beyond blood pressure reduction.
Main Methods:
- Systematic review of English literature from PubMed.
- Inclusion of clinical and pre-clinical study data.
- Keywords: azilsartan medoxomil, ARB, ACEi, hypertension.
Main Results:
- Azilsartan medoxomil showed greater effectiveness in reducing mean 24-hour systolic blood pressure compared to other ARBs and ramipril (an ACE inhibitor).
- The safety and tolerability profile of azilsartan medoxomil was comparable to existing treatments.
- Azilsartan medoxomil exhibits high affinity and slow dissociation from the AT1 receptor.
Conclusions:
- Azilsartan medoxomil is a highly efficacious ARB for blood pressure reduction.
- Its unique receptor binding properties suggest potential therapeutic advantages.
- Potential benefits include counteracting cardiac hypertrophy, fibrosis, insulin resistance, and improving renal protection and plaque stabilization.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.9K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.7K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.7K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.7K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
531
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
531
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
1.8K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.8K